Nike Reports Results… And Economic Track Records Ahead Of Presidential Debate 6/27/24
CNBC's "Fast Money"
00:00
Analysis of CEO surprise and impact of FDA proposal on Hymns and Hers drugs
The chapter explores a CEO's shock at the company's optimistic forecast, the strategy of store reduction for profitability, and the environmental influences on stock performance. It also delves into Hymns and Hers' challenges with their unapproved GLP-1 drugs and the potential effects of an FDA proposal on these products.
Play episode from 22:34
Transcript
